Myocarditis in Adolescents (12-17 years) Associated with the Pfizer-BioNTech (BNT162b2) Vaccine: A Systematic Review and Meta-analysis

Authors

  • Don Mathew
  • Siddharth Agarwal
  • Akil Sherif
  • Karandeep Bumrah

DOI:

https://doi.org/10.47672/ajhmn.1387

Keywords:

Myocarditis, BNT162b2, adolescent

Abstract

Purpose: Data on the incidence rate of myocarditis associated with mRNA COVID-19 vaccines in adolescents is limited. The research estimated the incidence of myocarditis associated with the Pfizer- BioNTech COVID-19 vaccine (BNT162b2) in adolescents (12-17 years).   

Methodology: This study was conducted as per the Meta-analysis of Observational Studies in Epidemiology (MOOSE) guidelines. Incidence rates were estimated after generating a random effects model.

Findings: The Incidence rate in males after the first dose was 2.4 per 100,000 persons (0.8- 6.8 per 100,000; I2: 17.17%). The IR in females after the first dose was 1.9 per 100,000 persons (0.5-6.5 per 100,000; I2: 0.00). After the second dose, the IR in males was 15.7 per 100,000 persons (3.2-78.1 per 100,000; I2: 96.45%), while in females the IR after the second dose was 6.1 per 100,000 persons (2.9-12.1 per 100,000; I2: 0.00). The Incidence Rate Ratio (IRR) after the first dose between males and females was 1.86 (0.40-8.5; I2: 0.00) and 6.35 (2.98-13.49; I2: 0.00) after the second dose. Among individuals between 12- 17 years of age, myocarditis is a rare side effect associated with Pfizer- BioNTech COVID-19 vaccine (BNT162b2) vaccination. The incidence in males were about two times greater than females following the first dose and six times greater following the second dose.

Recommendation: Vaccination strategy in adolescent males needs to be revisited to mitigate risk of myocarditis.

 

Downloads

Download data is not yet available.

Author Biographies

Don Mathew

Department of Internal Medicine, University of Pittsburgh Medical Center (UPMC), Pittsburgh, Pennsylvania

Siddharth Agarwal

Department of Internal Medicine, University of Pittsburgh Medical Center (UPMC), Pittsburgh, Pennsylvania

Akil Sherif

Department of Cardiology, St Vincent Hospital, Worcester, Massachusetts

Karandeep Bumrah

Department of Internal Medicine, University of Pittsburgh Medical Center (UPMC), Pittsburgh, Pennsylvania

References

Us_Fda. Comirnaty and Pfizer-BioNTech COVID-19 Vaccine | FDA. 2022;

Us_Fda. Spikevax and Moderna COVID-19 Vaccine | FDA. 2022;

Halsell JS, Riddle JR, Atwood JE, et al. Myopericarditis Following Smallpox Vaccination Among Vaccinia-Naive US Military Personnel. JAMA. 2003; 289(24):3283-3289. doi:10.1001/jama.289.24.3283

Klein NP, Lewis N, Goddard K, et al. Surveillance for Adverse Events after COVID-19 mRNA Vaccination. JAMA - Journal of the American Medical Association. 2021;326 (14):1390-1399. doi:10.1001/jama.2021.15072

Kim RJ, Kim HW, Jenista ER, et al. Patients with acute myocarditis following mrna covid-19 vaccination. JAMA Cardiology. 2021;6(10):1196-1201. doi:10.1001/jamacardio.2021.2828

Block JP, Boehmer TK, Forrest CB, et al. Cardiac Complications After SARS-CoV-2 Infection and mRNA COVID-19 Vaccination - PCORnet, United States, January 2021-January 2022. MMWR Morb Mortal Wkly Rep. Apr 8 2022;71(14):517-523. doi:10.15585/mmwr.mm7114e1

Husby A, Hansen JV, Fosbøl E, et al. SARS-CoV-2 vaccination and myocarditis or myopericarditis: population based cohort study. Bmj. Dec 16 2021;375:e068665. doi:10.1136/bmj-2021-068665

Karlstad Ø, Hovi P, Husby A, et al. SARS-CoV-2 Vaccination and Myocarditis in a Nordic Cohort Study of 23 Million Residents. JAMA Cardiol. Jun 1 2022;7(6):600-612. doi:10.1001/jamacardio.2022.0583

Oster ME, Shay DK, Su JR, et al. Myocarditis Cases Reported After mRNA-Based COVID-19 Vaccination in the US From December 2020 to August 2021. Jama. Jan 25 2022;327(4):331-340. doi:10.1001/jama.2021.24110

Patone M, Mei XW, Handunnetthi L, et al. Risks of myocarditis, pericarditis, and cardiac arrhythmias associated with COVID-19 vaccination or SARS-CoV-2 infection. Nat Med. Feb 2022;28(2):410-422. doi:10.1038/s41591-021-01630-0

Wong H-L, Hu M, Zhou CK, et al. Risk of myocarditis and pericarditis after the COVID-19 mRNA vaccination in the USA: a cohort study in claims databases. The Lancet. 2022;399(10342):2191-2199. doi:10.1016/S0140-6736(22)00791-7

Barda N, Dagan N, Ben-Shlomo Y, et al. Safety of the BNT162b2 mRNA Covid-19 vaccine in a nationwide setting. New England Journal of Medicine. 2021;385(12):1078-1090. doi:10.1056/NEJMoa2110475

Witberg G, Barda N, Hoss S, et al. Myocarditis after Covid-19 Vaccination in a Large Health Care Organization. N Engl J Med. Dec 2 2021;385(23):2132-2139. doi:10.1056/NEJMoa2110737

Mevorach D, Anis E, Cedar N, et al. Myocarditis after BNT162b2 mRNA Vaccine against Covid-19 in Israel. N Engl J Med. Dec 2 2021; 385 (23):2140-2149. doi:10.1056/NEJMoa2109730

Brooke BS, Schwartz TA, Pawlik TM. MOOSE Reporting Guidelines for Meta-analyses of Observational Studies. JAMA Surgery. 2021; 156 (8):787-788. doi:10.1001/jamasurg.2021.0522

Wells GA, Wells G, Shea B, et al. The Newcastle-Ottawa Scale (NOS) for Assessing the Quality of Nonrandomised Studies in Meta-Analyses. 2014:

Viechtbauer W. Conducting Meta-Analyses in R with the metafor Package. Journal of Statistical Software. 08/05 2010; 36 (3):1 - 48. doi:10.18637/jss.v036.i03

Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003; 327 (7414):557-560. doi:10.1136/bmj.327.7414.557

Mevorach D, Anis E, Cedar N, et al. Myocarditis after BNT162b2 Vaccination in Israeli Adolescents. New England Journal of Medicine. 2022; 386 (10):998-999. doi:10.1056/NEJMc2116999

Buchan SA, Seo CY, Johnson C, et al. Epidemiology of Myocarditis and Pericarditis Following mRNA Vaccination by Vaccine Product, Schedule, and Interdose Interval Among Adolescents and Adults in Ontario, Canada. JAMA Netw Open. Jun 1 2022;5(6):e2218505. doi:10.1001/jamanetworkopen.2022.18505

Wong HL, Hu M, Zhou CK, et al. Risk of myocarditis and pericarditis after the COVID-19 mRNA vaccination in the USA: a cohort study in claims databases. Lancet. Jun 11 2022;399(10342):2191-2199. doi:10.1016/s0140-6736(22)00791-7

Li X, Lai FTT, Chua GT, et al. Myocarditis Following COVID-19 BNT162b2 Vaccination Among Adolescents in Hong Kong. JAMA Pediatrics. 2022;176(6):612-614. doi:10.1001/jamapediatrics.2022.0101

Klein NP, Lewis N, Goddard K, et al. Surveillance for Adverse Events After COVID-19 mRNA Vaccination. Jama. Oct 12 2021;326(14):1390-1399. doi:10.1001/jama.2021.15072

Jain SS, Steele JM, Fonseca B, et al. COVID-19 Vaccination-Associated Myocarditis in Adolescents. Pediatrics. Nov 2021;148(5)doi:10.1542/peds.2021-053427

Chua GT, Kwan MYW, Chui CSL, et al. Epidemiology of Acute Myocarditis/Pericarditis in Hong Kong Adolescents Following Comirnaty Vaccination. Clin Infect Dis. Nov 28 2021;doi:10.1093/cid/ciab989

June Choe Y, Yi S, Hwang I, et al. Safety and effectiveness of BNT162b2 mRNA Covid-19 vaccine in adolescents. Vaccine. Jan 31 2022;40(5):691-694. doi:10.1016/j.vaccine.2021.12.044

Foltran D, Delmas C, Flumian C, et al. Myocarditis and pericarditis in adolescents after first and second doses of mRNA COVID-19 vaccines. Eur Heart J Qual Care Clin Outcomes. Mar 2 2022;8(2):99-103. doi:10.1093/ehjqcco/qcab090

Sharff KA, Dancoes DM, Longueil JL, Johnson ES, Lewis PF. Risk of myopericarditis following COVID-19 mRNA vaccination in a large integrated health system: A comparison of completeness and timeliness of two methods. Pharmacoepidemiol Drug Saf. Aug 2022;31(8):921-925. doi:10.1002/pds.5439

Bozkurt B, Kamat I, Hotez PJ. Myocarditis with COVID-19 mRNA Vaccines. Circulation. 2021:471-484. doi:10.1161/CIRCULATIONAHA.121.056135

Choi S, Lee S, Seo JW, et al. Myocarditis-induced Sudden Death after BNT162b2 mRNA COVID-19 Vaccination in Korea: Case Report Focusing on Histopathological Findings. J Korean Med Sci. Oct 18 2021;36(40):e286. doi:10.3346/jkms.2021.36.e286

Verma AK, Lavine KJ, Lin CY. Myocarditis after Covid-19 mRNA Vaccination. N Engl J Med. Sep 30 2021;385(14):1332-1334. doi:10.1056/NEJMc2109975

Fairweather D, Cooper LT, Jr., Blauwet LA. Sex and gender differences in myocarditis and dilated cardiomyopathy. Curr Probl Cardiol. Jan 2013;38(1):7-46. doi:10.1016/j.cpcardiol.2012.07.003.

Centers for Disease Control and Prevention. "Summary document for interim clinical considerations for use of COVID-19 vaccines currently authorized or approved in the United States". https://www.cdc.gov/vaccines/covid-19/downloads/summary-interim-clinical-considerations.pdf. Accessed on July,28,2022;

Downloads

Published

2023-03-27

How to Cite

Mathew, D. ., Agarwal, S. ., Sherif, A., & Bumrah, K. (2023). Myocarditis in Adolescents (12-17 years) Associated with the Pfizer-BioNTech (BNT162b2) Vaccine: A Systematic Review and Meta-analysis. American Journal of Health, Medicine and Nursing Practice, 8(2), 10–18. https://doi.org/10.47672/ajhmn.1387